BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21424129)

  • 21. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
    Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arginine deiminase, a potential anti-tumor drug.
    Ni Y; Schwaneberg U; Sun ZH
    Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
    Savaraj N; Wu C; Kuo MT; You M; Wangpaichitr M; Robles C; Spector S; Feun L
    Drug Target Insights; 2007; 2():119-28. PubMed ID: 21901069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
    Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
    Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes.
    Bobak YP; Vynnytska BO; Kurlishchuk YV; Sibirny AA; Stasyk OV
    Cell Biol Int; 2010 Nov; 34(11):1085-9. PubMed ID: 20653567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
    Sugimura K; Ohno T; Kusuyama T; Azuma I
    Melanoma Res; 1992 Sep; 2(3):191-6. PubMed ID: 1450673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
    Tsai WB; Aiba I; Lee SY; Feun L; Savaraj N; Kuo MT
    Mol Cancer Ther; 2009 Dec; 8(12):3223-33. PubMed ID: 19934275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects.
    Nagasaka H; Tsukahara H; Yorifuji T; Miida T; Murayama K; Tsuruoka T; Takatani T; Kanazawa M; Kobayashi K; Okano Y; Takayanagi M
    Metabolism; 2009 Mar; 58(3):278-82. PubMed ID: 19217439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
    Shu XL; Liu XL; Zhong JX; Liu J
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2124-31. PubMed ID: 25070816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
    Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
    Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
    Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
    Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy.
    Walts AE; Bomalaski JS; Ines D; Orsulic S
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1363-9. PubMed ID: 25548129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.
    Roeksomtawin S; Navasumrit P; Waraprasit S; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Savaraj N; Ruchirawat M
    Oncol Lett; 2018 Aug; 16(2):1529-1538. PubMed ID: 30008833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of argininosuccinate synthetase in rat brain glial cells after striatal microinjection of immunostimulants.
    Heneka MT; Schmidlin A; Wiesinger H
    J Cereb Blood Flow Metab; 1999 Aug; 19(8):898-907. PubMed ID: 10458597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
    Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
    Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.
    Agrawal V; Woo JH; Mauldin JP; Jo C; Stone EM; Georgiou G; Frankel AE
    Anticancer Drugs; 2012 Jan; 23(1):51-64. PubMed ID: 21955999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins.
    Park H; Lee JB; Shim YJ; Shin YJ; Jeong SY; Oh J; Park GH; Lee KH; Min BH
    Mol Cells; 2008 Apr; 25(2):305-11. PubMed ID: 18414006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
    Miraki-Moud F; Ghazaly E; Ariza-McNaughton L; Hodby KA; Clear A; Anjos-Afonso F; Liapis K; Grantham M; Sohrabi F; Cavenagh J; Bomalaski JS; Gribben JG; Szlosarek PW; Bonnet D; Taussig DC
    Blood; 2015 Jun; 125(26):4060-8. PubMed ID: 25896651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.
    Dillon BJ; Prieto VG; Curley SA; Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer; 2004 Feb; 100(4):826-33. PubMed ID: 14770441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.